全球生物医药产业正在进入一场静默的“权利转移”时刻。当海外巨头正在陷入CAR-T领域同质化竞争时,中国Biotech已然站在了下一代技术制高点。科济药业5月12日披露的BCMA CAR-T产品CT0596的临床数据,不仅展示了60%可评估患者4周内达到sCR/CR的惊人疗效,更揭示了通用型CAR-T技术平台突破性迭代的秘密——实现接近自体疗法的临床效果,其首例患者持续缓解超4个月的早期数据,彻底...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.